Treatment of indolent lymphoma in Germany - Results of a representative population-based survey

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 2, 2011, Pages 204-211

  Schmidt, Christian ^a   Fetscher, Sebastian ^b   Görg, Christian ^c   Kornek, Peter ^d   Nusch, Arnd ^e   Kegel, Thomas ^f   Kellermann, Lenka ^g   Hiddemann, Wolfgang ^a   Fingerle Rowson, Guenter ^h   Dreyling, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d Braunschweig Central Hospital   (Germany)

^e Oncological Haematological Practice   (Germany)

^f MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^g Oncology Information Service   (Germany)

^h JANSSEN CILAG GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ASPIRATION BIOPSY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BONE SCINTISCANNING; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMMUNITY HOSPITAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; ECHOGRAPHY; ERYTHROCYTE TRANSFUSION; FOLLICULAR LYMPHOMA; GENERAL PRACTICE; GERMANY; HEART DISEASE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INDOLENT LYMPHOMA; KIDNEY DYSFUNCTION; LYMPH NODE BIOPSY; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PUNCH BIOPSY; REVIEW; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GERMANY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052793257     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.001     Document Type: Article

References (18)

1. Cancer facts figures 2009-2010 American Cancer Society http://www.cancer.org/ downloads
2. SEER Surveillance, Epidemiology, and End Results SEER Cancer Statistics Review, 2007 http://seer.cancer.gov/csr/1975-2004/
3. D. Baris, and S.H. Zahm Epidemiology of lymphomas Curr Opin Oncol 12 2000 383 394 (Pubitemid 32268873)
4. S.H. Swerdlow, E. Campo, and N.L. Harris WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed. 2008 WHO City, Country
5. N.L. Harris, E.S. Jaffe, and J. Diebold World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 J Clin Oncol 17 1999 3835 3849
6. M. Dreyling Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 suppl 4 2009 119 120
7. G. Hölscher, S. Schmidt, and M. Dreyling Epidemiologie maligner Lymphome M. Dreyling, Maligne Lymphome - Manual 2008 Publisher Munich, Germany
8. B.D. Cheson, S.J. Horning, and B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
9. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586 (Pubitemid 350002966)
10. B. Eichhorst, M. Hallek, and M. Dreyling Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 suppl 4 2009 iv102 iv104
11. J.W. Friedberg, M.D. Taylor, and J.R. Cerhan Follicular lymphoma in the United States: first report of the national LymphoCare study J Clin Oncol 27 2009 1202 1208
12. M. Herold, A. Haas, and S. Srock Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study J Clin Oncol 25 2007 1986 1992 (Pubitemid 46972781)
13. W. Hiddemann, M. Kneba, and M. Dreyling Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 106 2005 3725 3732 (Pubitemid 41742196)
14. R. Marcus, K. Imrie, and P. Solal-Celigny Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma J Clin Oncol 26 2008 4579 4586
15. G. Salles, N. Mounier, and S. de Guibert Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study Blood 112 2008 4824 4831
16. M. Hallek, G. Fingerle-Rowson, and A.-M. Fink First line treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an interantional group of investigators and the German CLL study group Blood (ASH Annual Meeting Abstracts) 114 22 2009 223 (#535)
17. T. Robak, A. Dmoszynska, and P. Solal-Céligny Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia J Clin Oncol 28 2010 1756 1765
18. M.J. Rummel, N. Niederle, and G. Maschmeyer Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL Blood (ASH Annual Meeting Abstracts) 114 22 2009 168 (#405)